Argenx to acquire Forte Biosciences for $2.2 billion, adding anti‑CD122 antibody program
read at Endpoints ↗DealPositive
Argenx announced a $2.2 billion cash transaction to purchase Forte Biosciences, a biotech focused on autoimmune therapies.
The acquisition brings Forte's anti‑CD122 monoclonal antibody, which is currently under investigation for treating autoimmune diseases, into Argenx's pipeline.
The purchase price is set at $77 per Forte share, payable in cash.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Argenx to pick up autoimmune biotech Forte Biosciences for $2.2B”
read at Endpoints ↗81 words · retrieved Jul 27
comments(0)
5-min edit window · permanent after that